» Articles » PMID: 33083396

Prolonged Prothrombin Time at Admission Predicts Poor Clinical Outcome in COVID-19 Patients

Overview
Specialty General Medicine
Date 2020 Oct 21
PMID 33083396
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prognostic value of coagulation disorder in coronavirus disease 2019 (COVID-19) patients should be demonstrated.

Aim: To investigate the abnormalities of coagulation parameters in the patients with COVID-19 and their prognostic values.

Methods: Consecutive patients admitted in the isolation ward of Renmin Hospital of Wuhan University from January 31 to February 5, 2020 with confirmed COVID-19 were included. The primary outcomes were death and survival as of March 11. Demographics, vital signs, comorbidities and laboratory tests were collected and compared between those who died and survivors. Logistic regression analysis for prognostic factors was performed. Kaplan-Meier analysis was used to compare the estimated survival rate between patients with prolonged prothrombin time and normal prothrombin time.

Results: The total number of patients with confirmed COVID-19 who were enrolled was 213. The median age was 62 years, and 95 patients (44.6%) were men. Fifty-one patients were critical (23.9%), 79 patients were severe (37.1%) and 83 patients were moderate (39%). As of March 11, 2020, 99 patients were discharged (46.5%), 79 patients (37.1%) stayed in the hospital and 35 patients (16.2%) died. Median time to death was 6 (4-8) d, while median hospital stay was 32 (22-36) d in survivors ( < 0.001). More men ( = 0.002) and elderly patients ( < 0.001) were found in the group of those who died. The respiration rate at admission was higher in the group of those who died ( < 0.001). The incidences of hypertension ( = 0.028), cerebrovascular disease ( < 0.001), chronic kidney disease ( = 0.02) and chronic obstructive pulmonary disease ( < 0.001) were higher in the group of those who died. Platelet count was decreased in the group of those who died ( = 0.002) whereas prothrombin time ( < 0.001), activated partial thromboplastin time ( = 0.033), concentration of D-dimer ( < 0.001) and fibrin degradation products ( < 0.001) were increased in the group of those who died. Prothrombin time [odds ratio (OR): 2.19, = 0.004], respiration rate (OR: 1.223, < 0.001), age (OR: 1.074, < 0.001) and fibrin degradation products concentration (OR: 1.02, = 0.014) were predictors of death. The survival rate was significantly lower in patients with prolonged prothrombin time compare to those with normal prothrombin time ( < 0.001).

Conclusion: Prothrombin time, concentration of fibrin degradation products, respiration rate and age were predictive factors for clinical outcomes of COVID-19 patients.

Citing Articles

Unveiling coagulation dysfunction in patients with COVID-19: a retrospective analysis.

Jerah A, Farasani A, Abu-Tawil H, Kuriri H, Taha M, Abdelwahab S J Med Life. 2024; 17(9):886-891.

PMID: 39628975 PMC: 11611055. DOI: 10.25122/jml-2024-0166.


Analysis of Dengue and SARS-CoV-2 Coinfection in a Tertiary Care Hospital: A Retrospective Study.

Korishetty V, Rao P, Shenoy S, Jeppu U, B K J Trop Med. 2024; 2024:6788850.

PMID: 39345300 PMC: 11427724. DOI: 10.1155/2024/6788850.


Identification of Time-Series Pattern Marker in Its Application to Mortality Analysis of Pneumonia Patients in Intensive Care Unit.

Lee S, Kim S, Koh G, Ahn H J Pers Med. 2024; 14(8).

PMID: 39202004 PMC: 11355743. DOI: 10.3390/jpm14080812.


Hemostatic and liver function parameters as COVID-19 severity markers.

Iqbal Q, Mudatsir M, Harapan H, Nurjannah N, Maulana T Narra J. 2024; 4(1):e178.

PMID: 38798852 PMC: 11125416. DOI: 10.52225/narra.v4i1.178.


Systems-wide view of host-pathogen interactions across COVID-19 severities using integrated omics analysis.

Singh M, Pyati A, Rubi R, Subramanian R, Muley V, Ansari M iScience. 2024; 27(3):109087.

PMID: 38384846 PMC: 10879696. DOI: 10.1016/j.isci.2024.109087.


References
1.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

2.
Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

3.
Goeijenbier M, van Gorp E, van den Brand J, Stittelaar K, Bakhtiari K, Roelofs J . Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiol. 2014; 14:134. PMC: 4055237. DOI: 10.1186/1471-2180-14-134. View

4.
Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

5.
Thachil J, Warkentin T . How do we approach thrombocytopenia in critically ill patients?. Br J Haematol. 2016; 177(1):27-38. DOI: 10.1111/bjh.14482. View